Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

UPB

Upstream Bio Inc

Dec 13 • 04:00PM ET

20.25

Dollar change -0.16
Percentage change -0.78	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	70.41%	Shs Outstand	53.60M	Perf Week	-15.06%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-	Insider Trans	8.09%	Shs Float	15.19M	Perf Month	-21.84%
Income	-	PEG	-	EPS next Q	-0.56	Inst Own	8.35%	Short Float	7.94%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	3.43	Perf Half Y	-
Book/sh	-2.99	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.21M	Perf Year	-
Cash/sh	4.15	P/C	4.88	EPS next 5Y	-	ROE	-	52W Range	17.09 - 29.46	Perf YTD	-7.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-31.26%	Beta	-
Dividend TTM	-	Quick Ratio	20.90	Sales past 5Y	96.37%	Gross Margin	-	52W Low	18.50%	ATR (14)	2.07
Dividend Ex-Date	-	Current Ratio	20.90	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	42.43	Volatility	10.96% 10.50%
Employees	35	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	52.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.81	Prev Close	20.41
Sales Surprise	33.34%	EPS Surprise	-0.41%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	351.74K	Price	20.25
SMA20	-4.60%	SMA50	-13.49%	SMA200	-13.49%	Trades		Volume	285,430	Change	-0.78%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	Piper Sandler	Overweight	$75
Nov-05-24	Initiated	JP Morgan	Overweight	$38

Nov-21-24 08:00AM	Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 07:11AM	Upstream Bio reports Q3 revenue $607,000 vs $621,000 last year (TipRanks)
Nov-07-24 07:00AM	Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-17-24 07:02PM	Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc (GuruFocus.com) +9.66%
Oct-15-24 04:15PM	Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
06:45AM	Loading…
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +6.27%
Oct-10-24 07:35PM	Upstream Bio Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:19 PM
ORBIMED ADVISORS LLC	Director	Oct 15 '24	Buy	17.00	825,000	14,025,000	4,554,873	Oct 17 04:17 PM
AI Upstream LLC	10% Owner	Oct 15 '24	Buy	17.00	1,175,000	19,975,000	1,175,000	Oct 17 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UPB

Upstream Bio Inc

Upgrade your FINVIZ experience